SCHEMBL5383369

SCHEMBL5383369

O=C(NCCc1ccc(O)cc1)Nc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.79
MEN1 O00255 7/20 0.65
KMT2A Q03164 7/20 0.65
MAPT P10636 5/20 0.65
SMN1; SMN2 Q16637 4/20 0.65
CA12 O43570 1/20 0.62
CA1 P00915 1/20 0.62
CA2 P00918 1/20 0.62
CA4 P22748 1/20 0.62
CA5A P35218 1/20 0.62
CA7 P43166 1/20 0.62
CA9 Q16790 1/20 0.62
CA14 Q9ULX7 1/20 0.62
HTT P42858 4/20 0.60
POLB P06746 1/20 0.60
ALDH1A1 P00352 6/20 0.58
LMNA P02545 2/20 0.58
TP53 P04637 1/20 0.58
MAPK1 P28482 1/20 0.58
HSP90AA1 P07900 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4637913 0.88 CNR1 (0.77) CNR1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL22833985 0.88 CNR1 (1.00) CNR1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL19472774 0.88 CNR1 (0.62) CNR1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL15306496 0.88 CNR1 (0.77) CNR1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL15306499 0.88 CNR1 (0.77) CNR1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL15308418 0.88 MEN1 (0.78) CNR1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL6968982 0.88 CNR1 (0.76) CNR1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL6297252 0.86 CNR1 (0.70) CNR1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL15306498 0.86 CNR1 (0.73) CNR1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL4659127 0.86 CNR1 (0.73) CNR1MEN1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170298056-A1 SMALL MOLECULE INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2017-10-19 US disclosed
US-7183319-B2 Phenylethylamine derivatives and their use in the treatment of melanoma RILEY PATRICK ANTHONY 2007-02-27 US disclosed
US-20040029967-A1 Phenylethylamine derivatives and their use in the treatment of melanoma RILEY PATRICK ANTHONY (GB) 2004-02-12 US disclosed
EP-1303481-A1 PHENYLETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MELANOMA Riley, Patrick Anthony (GB) 2003-04-23 EP disclosed
WO-2002008174-A1 PHENYLETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MELANOMA RILEY PATRICK ANTHONY (GB) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298056-A1 SMALL MOLECULE INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF CD4, CCR5, CCR1 CNR1 984/4885MEN1 4090/4885KMT2A 4616/4885
US-20040029967-A1 Phenylethylamine derivatives and their use in the treatment of melanoma DOHH, DBH, HRH4 CNR1 121/4885MEN1 2544/4885KMT2A 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.